Early-stage embryos with abnormalities can still develop into healthy babies

Study shows that abnormal cells within embryos can be killed off by programmed cell death, and replaced by normal cells for healthy embryo development

Early-stage embryos with abnormalities can still develop into healthy babies

aneuploidybody.jpgNature Communications DOI: 10.1038/ncomms11165
Elimination of abnormal cells by apoptosis during blastocyst development. Showing sequential images from a time-lapse series of a 1:1 reversine chimera (control cells in this embryo are labelled with Tomato fluorescent protein), showing apoptosis of a reversine-treated cell (arrow), followed by engulfment of the apoptotic debris into an efferosome by a neighbouring control cell (star). Scale bar, 20 mm.

Abnormal cells in the early embryo are not necessarily a sign that a baby will be born with a birth defect such as Down’s syndrome, suggests new research from the University of Cambridge, the Wellcome Trust Sanger Institute and the University of Leuven, Belgium. In a study published today (29 March) in the journal Nature Communications, scientists show that abnormal cells are eliminated and replaced by healthy cells, repairing – and in many cases completely fixing – the embryo.

Researchers at the Department of Physiology, Development and Neuroscience at Cambridge report a mouse model of aneuploidy, where some cells in the embryo contain an abnormal number of chromosomes. Normally, each cell in the human embryo should contain 23 pairs of chromosomes (22 pairs of chromosomes and one pair of sex chromosomes), but some can carry multiple copies of chromosomes, which can lead to developmental disorders. For example, children born with three copies of chromosome 21 will develop Down’s syndrome.

Pregnant mothers – particular older mothers, whose offspring are at greatest risk of developing such disorders – are offered tests to predict the likelihood of genetic abnormalities. Between the 11th and 14th weeks of pregnancy, mothers may be offered chorionic villus sampling (CVS), a test that involves removing and analysing cells from the placenta. A later test, known as amniocentesis, involves analysing cells shed by the foetus into the surrounding amniotic fluid – this test is more accurate, but is usually carried out during weeks 15-20 of the pregnancy, when the foetus is further developed.

Professor Magdalena Zernicka-Goetz, the study’s senior author, was inspired to carry out the research following her own experience when pregnant with her second child. At the time, a CVS test found that as many as a quarter of the cells in the placenta that joined her and her developing baby were abnormal: could the developing baby also have abnormal cells? When Professor Zernicka-Goetz spoke to geneticists about the potential implications, she found that very little was understood about the fate of embryos containing abnormal cells and about the fate of these abnormal cells within the developing embryos.

Fortunately for Professor Zernicka-Goetz, her son, Simon, was born healthy.

“I am one of the growing number of women having children over the age of 40 – I was pregnant with my second child when I was 44. I know how lucky I was and how happy I felt when Simon was born healthy.”

"Many expectant mothers have to make a difficult choice about their pregnancy based on a test whose results we don’t fully understand. What does it mean if a quarter of the cells from the placenta carry a genetic abnormality – how likely is it that the child will have cells with this abnormality, too? This is the question we wanted to answer. Given that the average age at which women have their children is rising, this is a question that will become increasingly important.”

Professor Magdalena Zernicka-Goetz, a senior study author from the Department of Physiology, Development and Neuroscience, University of Cambridge

“In fact, abnormal cells with numerical and/or structural anomalies of chromosomes have been observed in as many as 80-90 per cent of human early-stage embryos following in vitro fertilization and CSV tests may expose some degree of these abnormalities.”

Professor Thierry Voet from the Wellcome Trust Sanger Institute, UK, and the University of Leuven, Belgium, another senior author of the paper

In research funded by the Wellcome Trust, Professor Zernicka-Goetz and colleagues developed a mouse model of aneuploidy by mixing 8-cell stage mouse embryos in which the cells were normal with embryos in which the cells were abnormal. Abnormal mouse embryos are relatively unusual, so the team used a molecule known as reversine to induce aneuploidy.

In embryos where the mix of normal and abnormal cells was half and half, the researchers observed that the abnormal cells within the embryo were killed off by ‘apoptosis’, or programmed cell death, even when placental cells retained abnormalities. This allowed the normal cells to take over, resulting in an embryo where all the cells were healthy. When the mix of cells was three abnormal cells to one normal cell, some of abnormal cells continued to survive, but the ratio of normal cells increased.

“The embryo has an amazing ability to correct itself. We found that even when half of the cells in the early-stage embryo are abnormal, the embryo can fully repair itself. This means that even when early indications suggest a child might have a birth defect because there are some, but importantly not all abnormal cells in its embryonic body, this isn’t necessarily the case.”

Professor Magdalena Zernicka-Goetz

The researchers will now try to determine the exact proportion of healthy cells needed to completely repair an embryo and the mechanism by which the abnormal cells are eliminated.

Notes to Editors
Publications
  • Mouse model of chromosome mosaicism reveals lineage-specific depletion of aneuploid cells and normal developmental potential.

    Bolton H, Graham SJ, Van der Aa N, Kumar P, Theunis K et al.

    Nature communications 2016;7;11165

Selected Websites
Contact the Press Office

Dr Samantha Wynne

Media Officer

Wellcome Trust Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Tel +44 (0)1223 492 368

Mobile +44 (0) 7900 607793

Fax +44 (0)1223 494 919

Recent News

Babies' DNA affects mothers' risk of pre-eclampsia in pregnancy

Strong evidence found for a number of genetic variations near to the FLT1 gene being linked to increased risk of pre-eclampsia

Hidden lives revealed in a new exhibition at the Wellcome Genome Campus

The Hidden Lives exhibition offers an exciting insight into the lives and origins of our East Anglian ancestors, greatly enriched from the insight afforded through genomic technology.

Chan Zuckerberg Initiative supports Human Cell Atlas data platform

The Data Coordination Platform will check, share and analyse the vast amounts of diverse information generated